IPHANASDAQHealthcare · Biotechnology

Innate Pharma S.A.

$2.20+8.37%(+$0.17)

TickerSpark Score

52/100

Mixed

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IPHA research report →

52-Week Range71% of range

Low $1.17

Current $2.20

High $2.63

Companywww.innate-pharma.com

Innate Pharma S. A. , a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally.

CEO: Jonathan E. Dickinson
IPO: 2019
Employees: 181
HQ: Marseille, FR

Price Chart

+4.48% · this period

Valuation

Market Cap: $206.59M
P/E: -3.64
P/S: 66.04
P/B: -8.25
EV/EBITDA: -3.19
Div Yield: 0.00%

Profitability

Gross Margin: 100.00%
Op Margin: -2058.02%
Net Margin: -1764.51%
ROE: 593.93%
ROIC: -155.52%

Growth & Income

Revenue: $2.79M · -77.92%
Net Income: $-49,177,000 · 0.59%
EPS: $-0.53 · 13.11%
Op Income: $-53,425,000
FCF YoY: -597.23%

Performance & Tape

52W High: $2.63
52W Low: $1.17
50D MA: $1.47
200D MA: $1.80
Beta: 0.81
Avg Volume: 66.84K

Get TickerSpark's AI analysis on IPHA

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime